No abstract

Hyperthermia or hypothermia alone has shown promising results in killing cancer cells as monotherapy, or as adjunct or alternative therapy. We asked whether combination of hyper-, hypothermia therapy (HIT) worked better than single treatment on cancer cells. Murine colon cancer (CT-26) cells, human basal cell carcinoma (BCC) and human melanoma A375 cells were treated with HIT. Only 30 % of the cells survived after onc cycle of hyperthermia (45 C for 10 minutes) and hypothermia (-10 C for 1 second) treatment in all cell types. Five cycles HIT killed all cells. In addition, HIT enhanced the susceptibility of melanoma cell to chemotherapeutic agent dacarbazine (DTIC). These results suggest HIT might be a potential new anti-cancer therapy.Gastric cancer is one of the most common malignant tumors in China with a very high mortality. But nowadays it encounters a dilemma-multidrug resistance (MDR). In our earlier studies, we found that TGFb1 could enhance the invasion and metastasis of gastric cancer and induce the expression of GST-p, indicating that TGFb1 might involve in drug-resistance of gastric cancer. To test this hypothesis, we conducted MTT assay and found that S30Abstracts / Cell Biology International 32 (2008) S1eS67